Table 1.
Patient Characteristics
| n = 60 | |
|---|---|
| Median age (25th–75th percentile) | 60 Years (51–69) |
| Male, n (%) | 33 (55) |
| ECOG performance status, n (%) | |
| 0 | 37 (61.7) |
| 1 | 19 (31.7) |
| 2 | 4 (6.7) |
| Histological subtype, n (%) | |
| Follicular | 16 (26.7) |
| Hürthle cell | 8 (13.3) |
| Papillary | 36 (60.0) |
| Prior radiation | 35 (58.3) |
| No. of prior systemic therapies, n (%) | |
| 0 | 4 (6.7) |
| 1 | 40 (66.7) |
| 2–4 | 16 (22.7) |
| Prior systemic therapies, n (%) | |
| Radioiodine | 54 (90.0) |
| Sorafenib ± Everolimus (trial) | 6 (10.0) |
| Lenalidomide | 3 (5.0) |
| Panobinostat | 2 (3.3) |
| Bexarotene | 2 (3.3) |
| DepsiPeptide | 1 (1.7) |
| Doxorubicin ± cisplatin | 1 (1.7) |
| Gemcitabine | 1 (1.7) |
| Lenvatinib | 1 (1.7) |
| Octreotide | 1 (1.7) |
| Sirolimus | 1 (1.7) |
| Strontium 89 | 1 (1.7) |
| Sunitinib | 1 (1.7) |
| Sites of metastatic disease, n (%) | |
| Lung | 54 (90.0) |
| Nodes | 45 (75.0) |
| Bone | 21 (35.0) |
| Liver | 8 (13.3) |
| Subcutaneous/soft tissue | 6 (10.0) |
| Trachea ± larynx | 2 (3.3) |
| Abdomen | 1 (1.7) |
| Brain | 1 (1.7) |
| Symptoms at registration, n (%) | |
| Grade 3 hypertension | 1 (1.7) |
| Grade 2 hypertension | 1 (1.7) |
| Grade 1 hypertension | 15 (25.0) |
| Grade 1 fatigue | 19 (31.7) |
| Grade 1 anorexia | 2 (3.3) |
| Grade 2 anemia | 3 (5.0) |
| Grade 1 anemia | 15 (30.0) |
| Narcotic use | 11 (18.3) |
| Hypertension medication use | 34 (56.7) |
ECOG, Eastern Cooperative Oncology Group.